NCT06027983View on ClinicalTrials.gov

Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 1, 2026

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
HER2+ Advanced Breast CancerOther Solid Tumors
Interventions
DRUG

Chimeric receptor T-cells + Trastuzumab

Chimeric receptor T-cells will be administered by infusion. Trastuzumab will be administered intravenously.

DRUG

Fludarabine and Cyclophosphosphamide

3-day chemotherapy regimen of fludarabine and cyclophosphamide for lymphodepletion

All Listed Sponsors
lead

National University Hospital, Singapore

OTHER